Skip to main content
. 2023 Apr 27;41(17):3203–3216. doi: 10.1200/JCO.22.02390

FIG 2.

FIG 2.

Disease control outcomes: (A) OS, (B) prostate cancer–specific mortality, (C) distant metastasis, (D) PSA progression, (E) rates of salvage ADT, and (F) non–prostate cancer–specific mortality. ADT, androgen-deprivation therapy; HR, hazard ratio; OS, overall survival; PSA, prostate-specific antigen; RT, radiotherapy; STAD, short-term androgen deprivation.